Investigating the Effects of Cannabidiol on Social Anxiety Disorder

Part of paid clinical trials in Cambridge, Massachusetts.

Sponsor
Massachusetts Institute of Technology
Study ID
NCT05649059
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Phobia, Social

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • Cannabidiol — DRUG
    Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
  • Placebo — DRUG
    Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.

Study Details

The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).

Key Dates

Start date
Jul 10, 2025
Status verified
Nov 2025
Primary completion
May 31, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Active Comparator: Cannabidiol
    300mg Cannabidiol (3mL Epidiolex), oral, single-dose
  • Placebo Comparator: Placebo
    Placebo (3mL sesame seed oil), oral, single-dose

Primary Outcome Measure

Change in Acute Subjective Anxiety [ Time Frame: -180 minutes, -15 minutes, -5 minutes, +10 minutes, +20 minutes, +30 minutes ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts Institute of TechnologyCambridgeMassachusetts02139
Omar Rutledge, MS
[email protected]
617-324-2898
John Gabrieli, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cambridge, MA

By research site
Massachusetts Institute of Technology· Cambridge, MA